Bitcoin (BTC) options set to expire on December 25, 2026, will settle in cash rather than through Bitcoin delivery. These options, traded on Deribit, follow a quarterly expiration schedule with the final settlement price determined by a 30-minute time-weighted average price (TWAP) from 07:30 to 08:00 UTC. This process ensures a fair and transparent closing price for the contracts. Investors holding these options should note the exact expiration time at 08:00 UTC on the final Friday of the quarter.
Bitcoin options expiration timing provides context for cryptocurrency market activity on Pluang as of Oct 23, 2026 06:32 WIB. Of 50 major cryptocurrencies priced, only 4 rose while 45 fell. Among notable movers, VET dropped 6.76% to Rp128 with a balanced 50% sell/buy order split and a typical hold time of 148 days, contrasting with SNX which fell 6.65% to Rp3,833 and has a shorter hold time of 70 days and a slight buy bias at 52%. UNI also declined 6.54% to Rp126,086, showing a stronger buy interest at 66% and a hold time of 65 days.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Lycia Therapeutics, a biotech company developing therapies targeting disease-causing proteins, priced its upsized initial public offering at $18 per share, raising approximately $317.5 million before expenses. The company plans to use the funds to ad...
